KLOW and GLOW Peptide Blends: What Is in Each Vial and What the Research Shows

KLOW and GLOW are names coined by the peptide market, not by a laboratory. They sound like products with a mechanism; in fact each is a mixture of separately researched molecules, and the mixture itself has never been the subject of a published experiment. This page separates the two layers: what is known about each molecule, in which model, and what is simply not known about putting them together.

What is the KLOW peptide blend, and what is the GLOW peptide blend?

GLOW combines three peptides that appear in tissue-repair research: the copper tripeptide GHK-Cu, the synthetic 15-residue peptide BPC-157, and TB-500, a short synthetic fragment linked to the protein thymosin β4. KLOW adds a fourth, KPV, the Lys-Pro-Val tripeptide that forms the C-terminal end of α-melanocyte-stimulating hormone (α-MSH). The “K” in KLOW stands for that addition.

The amounts below are the ones declared on Condor’s own KLOW and GLOW vials. The last two columns are our arithmetic, and they change how the blends should be read.

Composition of the KLOW and GLOW blends as declared on Condor Research product pages, October 2026. Mass shares calculated by Condor Research. Other suppliers may use different amounts under the same names; the label, not the name, defines the material.

62.5% of the peptide mass in a KLOW vial is GHK-Cu. By weight, both blends are a copper-peptide vial with three smaller additions, not an even four-way or three-way mix.

KLOW vs GLOW: what is the actual difference between the two blends?

The difference is one component. The three shared peptides are present in the same amounts in both vials, so GLOW is not a “lighter” KLOW and KLOW is not a reformulated GLOW: it is GLOW with 10 mg of KPV added. Everything that distinguishes the two at the level of evidence therefore comes down to what is known about KPV.

The names carry no regulatory or chemical definition. They work as shorthand within the market, and composition varies between vendors. In Condor’s KLOW and GLOW vials the TB-500 component is the 7-residue thymosin β4 fragment 17–23 (Ac-LKKTETQ, about 889 Da), not full-length thymosin β4. A related two-peptide product, GHK-Cu with KPV, is sold under at least five naming conventions; our survey of GHK-Cu + KPV naming shows how quickly these labels drift.

What has research on each KLOW and GLOW component actually studied?

What follows is organised by component and, within each, by the level of the evidence: in vitro (cells or tissue in a dish), animal, and human. The distinction matters more than any single result, because the popular claims for both blends tend to come from the first two levels and are then read as if they came from the third.

GHK-Cu in KLOW and GLOW: from serum factor to skin-care ingredient

GHK was first described in 1973 as a factor in human serum that changed the behaviour of liver cells in culture [1]. Its copper complex later became a reference compound in connective-tissue research, and the review literature on it is written largely by the group that discovered it [7].

• In vitro. In fibroblast cultures, the GHK-copper complex increased collagen synthesis [2]. In isolated human hair follicles it stimulated elongation ex vivo and proliferation of dermal papilla cells [3]. Analyses of gene-expression datasets attribute to GHK a broad transcriptional footprint, a computational inference rather than a measured outcome in an organism [4].
• Animal. In rats with ischaemic open wounds, a topical gel of the tripeptide-copper complex was associated with faster wound contraction and lower TNF-α and MMP-2/9 levels than vehicle or no treatment [5].
• Human. The only PubMed record tagged as a controlled trial is small and topical: 13 patients after CO₂ laser resurfacing, randomised to skin-care products with or without GHK-Cu. Blinded and software measures found no difference in redness, wrinkles or overall skin quality; only the patients’ own questionnaire favoured GHK-Cu [6]. Every registered GHK-Cu study on ClinicalTrials.gov concerns topical or patch use [29].

The human record for GHK-Cu is cosmetic and topical. Nothing in it describes GHK-Cu as it is supplied in a lyophilised blend. For the full picture see our GHK-Cu primer.

BPC-157 in KLOW and GLOW: a large rodent literature from one centre

BPC-157 is a synthetic 15-residue sequence described as a fragment of a gastric protein.

• In vitro. In cultured rat tendon fibroblasts, BPC-157 increased outgrowth, survival under oxidative stress and migration [8]; an earlier paper reported growth of tendocytes in culture [9].
• Animal. The same 2003 paper reported faster functional and histological recovery of a transected Achilles tendon in rats [9]. The wider rodent literature covers gut, muscle, vessel and nervous-system models, and much of it comes from a single research group in Zagreb [10]. Independent reviewers describe the animal evidence as broad but note that replication outside that group is limited [11].
• Human. PubMed indexes no randomised or controlled trial. Two small uncontrolled reports from one US clinic exist: a retrospective telephone survey of 16 patients (2021) and a two-person safety pilot (2025) [12][13]. Neither has a control group. Four studies naming BPC-157 are registered on ClinicalTrials.gov, none of them a blend [29].

Deeper coverage: what BPC-157 is and how it has been studied.

TB-500 in KLOW and GLOW: the fragment is not the protein

This is the component most often misdescribed. Thymosin β4 is a 43-residue protein that binds actin. TB-500, as identified by anti-doping chemists in a product seized for analysis, is a much shorter molecule: the N-terminally acetylated 17–23 fragment, Ac-LKKTETQ [14]. The FDA uses the same identity, “thymosin beta-4, fragment (LKKTETQ), also known as TB-500” [27].

• In vitro and animal (full protein). Thymosin β4 was associated with faster closure of full-thickness wounds in rats and with keratinocyte migration in culture [15], with cardiomyocyte migration and survival and cardiac repair in mice [16], and with hair growth through follicle stem-cell migration in rats and mice [17]. Its basic biology and early clinical programme were reviewed in 2012 [26].
• Human (full protein only). Thymosin β4 itself has reached clinical testing: a placebo-controlled phase I study of the intravenous protein in healthy volunteers [18], a phase II study in venous ulcers [19] and a phase 2 trial of eye drops in severe dry eye [20].
• Human (TB-500 fragment). None indexed in PubMed. The FDA states it “has not identified any human exposure data” for the fragment [27]. One study naming TB-500 is registered on ClinicalTrials.gov and is still recruiting [29].

The practical consequence: sources that cite thymosin β4 trials as evidence for TB-500 are describing a different molecule, roughly six times larger. See TB-500 full protein vs fragment and the TB-500 primer.

KPV in KLOW only: an inflammation-model tripeptide

KPV is the part of KLOW that GLOW lacks. It derives from α-MSH, whose anti-inflammatory activity in experimental systems was reviewed in depth in 2008 [25].

• In vitro. In intestinal epithelial cells, KPV enters through the PepT1 transporter and lowers inflammatory signalling [21]. Ex vivo, it has been driven across microporated human skin by iontophoresis, a delivery experiment rather than a biological outcome [24].
• Animal. In mouse models of colitis, KPV reduced markers of intestinal inflammation [21][22], and a KPV-binding hydrogel was studied for restoring the mucosal barrier in an inflamed colon [23].
• Human. No clinical trial in PubMed and none registered on ClinicalTrials.gov. The FDA states it has not identified any human exposure data for KPV by any route [27].

The fourth peptide brings an inflammation model to the blend, but its data come from gut models, not from skin or connective tissue. More in our KPV primer.

How much evidence exists for each KLOW and GLOW component? A dated count

We ran the same PubMed and ClinicalTrials.gov queries for every component on 5 October 2026 [30]. The “Humans” filter is a MeSH tag that also covers human cells and tissue, so it overstates clinical evidence; the trial column is the stricter measure.

Condor Research count, 5 October 2026. *The single TB-500 record carrying a clinical-trial tag is a tuberculosis study matched on the string “TB 500”; we exclude it. The thymosin β4 trial records include studies that measure the protein rather than give it. Queries are listed in reference 30 so the table can be reproduced.

Every number on this page that sounds like an effect belongs to one peptide, usually in one species of rodent. The blends have a name, a price and a following, but no dataset.

Does combining GHK-Cu, BPC-157, TB-500 and KPV in one vial change anything?

Nobody has measured it. The rationale for both blends is thematic: each component appears in some corner of tissue-repair or inflammation research, so together they are assumed to cover more ground. That is a hypothesis, and it leaves specific questions open:

• Chemistry in the vial. GHK-Cu is a metal complex. Whether its copper remains bound to GHK when the material is co-lyophilised and reconstituted alongside three other peptides has not been characterised for these blends in any published study we could find.
• Stability. Each peptide has its own degradation profile. Stability data for the mixtures as such are not in the literature.
• Interaction. Whether the components add, cancel or modify each other’s effects in any model is untested. The only human record we found that mentions two of the components given together (BPC-157 with thymosin β4, four patients in a retrospective survey) has no control group and cannot separate them [12].
• Attribution. Because the ratio is fixed at manufacture, an experiment using the blend cannot assign an observed effect to any single component. Component-level questions need single-peptide arms alongside the blend.

Our broader analysis of why stacked compounds multiply unknowns is in peptide stacks: what the evidence can and cannot say.

What are the “KLOW peptide benefits” and “GLOW peptide benefits” claims based on?

Searches for the “benefits” of these blends are common. The honest way to answer them is to trace each popular claim back to the component and the level of evidence it comes from.

Mapping of commonly repeated blend claims to their source literature. Compiled by Condor Research, October 2026. “Strongest evidence level” means the highest level found, not that the claim is supported at that level.

Read this way, “benefits” pages describe four literatures that rarely overlap in model, tissue or form. None of the claims has been examined for the blends themselves, and none of the human data concerns the lyophilised peptides as supplied in a research vial.

Regulatory status of the KLOW and GLOW components in 2026

• United States, FDA. BPC-157, KPV, GHK-Cu (for injectable routes) and the TB-500 fragment were placed in category 2 of the FDA’s bulk-substances interim policy, the list of substances that may present significant safety risks in compounding. On the page updated 22 April 2026 they appear in the table of substances whose nominations “were withdrawn by the nominators”, with FDA’s safety statements still published beside each [27]. A withdrawn nomination is not an approval.
• Sport, WADA. BPC-157 is prohibited under S0 (non-approved substances), and thymosin β4 and its derivatives, including TB-500, under S2 [28].
• European Union. None of the four is an authorised medicinal product. Condor supplies both blends only as research-use-only reference materials.

How to verify the identity of a KLOW or GLOW vial

A multi-peptide vial needs a certificate that resolves each component separately. Four checks are specific to these blends:

1. One mass per component. Expected [M+H]⁺ values: BPC-157 1419.71; TB-500 as Ac-LKKTETQ 889.50; GHK 341.19; KPV 343.23 (monoisotopic, calculated from sequence).
2. GHK and KPV resolved. In KLOW their masses differ by about 2 Da, so a low-resolution spectrum can merge them.
3. Which TB-500. The certificate should say whether the vial holds the 7-residue fragment or full thymosin β4 (about 4.96 kDa), and the observed mass should match. In Condor’s KLOW and GLOW the TB-500 component is the 7-residue fragment, Ac-LKKTETQ.
4. Ratio, not only total. A single purity figure for the whole vial cannot show whether the 50:10:10(:10) ratio matches the label. Copper content needs its own test.

Our COA methodology explains these tests, and the State of Analytical Evidence study shows how often published certificates omit them.

Limitations of this review

• PubMed counts depend on the query; synonyms and indexing lag can move them by a few records. Queries are published for that reason.
• The “Humans” MeSH tag includes work on human cells, so it is not a count of human studies.
• We summarise primary papers from their abstracts and full texts where available; effect sizes in animal models do not transfer to other species.
• Blend compositions differ between suppliers. This page describes the amounts declared on Condor’s vials.
• Condor Research sells both blends. The commercial interest is declared here; it is the reason every claim on this page is tied to a reference.